Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish
Mycobacterium abscessus is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combin...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
2024
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/173643 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| id |
sg-ntu-dr.10356-173643 |
|---|---|
| record_format |
dspace |
| spelling |
sg-ntu-dr.10356-1736432024-02-25T15:38:19Z Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish Goh, Boon Chong Larsson, Simon Dam, Linh Chi Ling, Sharon Yan Han Chua, Patrina Wei Lin Abirami, R. Singh, Samsher Ong, Ernest Jun Long Teo, Jeanette W. P. Ho, Peiying Ingham, Philip William Pethe, Kevin Dedon, Peter C. Lee Kong Chian School of Medicine (LKCMedicine) Institute of Molecular and Cell Biology, A*STAR Singapore Centre for Environmental Life Sciences and Engineering (SCELSE) Medicine, Health and Life Sciences Antibiotics Clarithromycin Mycobacterium abscessus is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments. Agency for Science, Technology and Research (A*STAR) National Research Foundation (NRF) Singapore-MIT Alliance for Research and Technology (SMART) Published version This work was funded by the A*STAR Singapore Therapeutics Development Review (H19H0G1003), the Singapore-MIT Alliance for Research and Technology (SMART) Innovation Centre (ING-000772 BIO IGN) and the SMART Antimicrobial Resistance IRG, which is supported by the National Research Foundation of Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) Program. 2024-02-20T07:49:35Z 2024-02-20T07:49:35Z 2023 Journal Article Goh, B. C., Larsson, S., Dam, L. C., Ling, S. Y. H., Chua, P. W. L., Abirami, R., Singh, S., Ong, E. J. L., Teo, J. W. P., Ho, P., Ingham, P. W., Pethe, K. & Dedon, P. C. (2023). Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish. JAC-Antimicrobial Resistance, 5(3), dlad052-. https://dx.doi.org/10.1093/jacamr/dlad052 2632-1823 https://hdl.handle.net/10356/173643 10.1093/jacamr/dlad052 37168836 2-s2.0-85161036544 3 5 dlad052 en H19H0G1003 ING-000772 BIO IGN JAC-Antimicrobial Resistance © 2023 The Author(s). Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/ by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. application/pdf |
| institution |
Nanyang Technological University |
| building |
NTU Library |
| continent |
Asia |
| country |
Singapore Singapore |
| content_provider |
NTU Library |
| collection |
DR-NTU |
| language |
English |
| topic |
Medicine, Health and Life Sciences Antibiotics Clarithromycin |
| spellingShingle |
Medicine, Health and Life Sciences Antibiotics Clarithromycin Goh, Boon Chong Larsson, Simon Dam, Linh Chi Ling, Sharon Yan Han Chua, Patrina Wei Lin Abirami, R. Singh, Samsher Ong, Ernest Jun Long Teo, Jeanette W. P. Ho, Peiying Ingham, Philip William Pethe, Kevin Dedon, Peter C. Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish |
| description |
Mycobacterium abscessus is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments. |
| author2 |
Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet |
Lee Kong Chian School of Medicine (LKCMedicine) Goh, Boon Chong Larsson, Simon Dam, Linh Chi Ling, Sharon Yan Han Chua, Patrina Wei Lin Abirami, R. Singh, Samsher Ong, Ernest Jun Long Teo, Jeanette W. P. Ho, Peiying Ingham, Philip William Pethe, Kevin Dedon, Peter C. |
| format |
Article |
| author |
Goh, Boon Chong Larsson, Simon Dam, Linh Chi Ling, Sharon Yan Han Chua, Patrina Wei Lin Abirami, R. Singh, Samsher Ong, Ernest Jun Long Teo, Jeanette W. P. Ho, Peiying Ingham, Philip William Pethe, Kevin Dedon, Peter C. |
| author_sort |
Goh, Boon Chong |
| title |
Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish |
| title_short |
Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish |
| title_full |
Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish |
| title_fullStr |
Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish |
| title_full_unstemmed |
Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish |
| title_sort |
rifaximin potentiates clarithromycin against mycobacterium abscessus in vitro and in zebrafish |
| publishDate |
2024 |
| url |
https://hdl.handle.net/10356/173643 |
| _version_ |
1794549476083367936 |